Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

536
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
536
Dementia01:30

Dementia

278
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Puppy Escape Narrative: Validation of an Openly Available Recall Task for MCI Detection.

medRxiv : the preprint server for health sciences·2026
Same author

The heat exposure, aging trajectories, and Alzheimer's disease (HEAT-AD) study protocol.

PloS one·2026
Same author

Defining and Measuring Cognitive Decline and Clinical Relevance.

Neurology and therapy·2026
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Redefining the norms: an interdisciplinary perspective on language testing in multilinguals with acquired and progressive neurogenic disorders.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Nov 11, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K

Screening for Early-Stage Alzheimer's Disease Using Optimized Feature Sets and Machine Learning.

Michael J Kleiman1, Elan Barenholtz2, James E Galvin1

  • 1Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.

Journal of Alzheimer'S Disease : JAD
|March 29, 2021
PubMed
Summary

Early detection of cognitive impairment is challenging. This study identified key cognitive tests for efficient screening, achieving high sensitivity for mild impairment detection.

Keywords:
Alzheimer’s diseasedata miningmild cognitive impairmentneuropsychological testssupervised machine learning

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.4K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

510

Related Experiment Videos

Last Updated: Nov 11, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.4K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

510

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Early-stage Alzheimer's disease detection is hindered by the lack of sensitive, practical cognitive assessments for mild impairment.
  • This contributes to a high rate of undetected dementia in clinical settings.

Purpose of the Study:

  • To identify optimal cognitive assessment features for detecting mild impairment and improving routine screening.
  • To compare the effectiveness of two-class (impaired/non-impaired) versus three-class (CDR 0, 0.5, 1) classification for dementia staging.

Main Methods:

  • Supervised feature selection was used to identify cognitive measurements for impairment (CDR 0.5+).
  • Random forest classifiers and stochastic cross-validation predicted impairment, with results analyzed using general linear models.

Main Results:

  • A two-class classification strategy significantly improved sensitivity and negative predictive values compared to a three-class approach.
  • Four features (Logical Memory, trail-making, memory questions) achieved 94.53% sensitivity in ~15 minutes.
  • Adding four more features increased sensitivity to 95.18%.

Conclusions:

  • A concise set of four cognitive features shows high detection rates for mild cognitive impairment (CDR 0.5+).
  • These features offer a practical foundation for developing effective cognitive impairment screening protocols.